Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Consensus Recommendation of “Moderate Buy” by Analysts

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) has received a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is $41.75.

A number of equities analysts recently weighed in on COAG shares. Jefferies Financial Group started coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They issued a “buy” rating and a $39.00 price target for the company. The Goldman Sachs Group started coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price target for the company. Wedbush started coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They issued an “outperform” rating and a $42.00 price target for the company. Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Finally, Zacks Research upgraded Hemab Therapeutics to a “hold” rating in a research report on Wednesday, May 27th.

Hemab Therapeutics Stock Performance

COAG opened at $25.41 on Friday. Hemab Therapeutics has a fifty-two week low of $23.00 and a fifty-two week high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Buying and Selling at Hemab Therapeutics

In related news, Director Ra Capital Management, L.P. purchased 2,675,000 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $48,150,000.00. Following the transaction, the director directly owned 6,149,096 shares of the company’s stock, valued at $110,683,728. This trade represents a 77.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last three months, insiders acquired 2,902,872 shares of company stock valued at $53,769,784.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.